VIRMA and liver cancer: In hepatitis B virus surface small antigen (SHBs)-induced liver cancer cells, SHBs upregulated VIRMA expression, mediating the m6A modification of CCR9 mRNA and enhancing its stability, thus promoting regorafenib resistance.